Bratton Capital Management L.P. Buys New Shares in Aquestive Therapeutics, Inc. $AQST

Key Points

• Bratton Capital Management acquired 9.81 million AQST shares, representing approximately 7.82% of Aquestive Therapeutics and its entire reported portfolio. Institutional investors collectively own 32.45% of the stock.
• Analyst sentiment remains generally positive, with a consensus “Buy” rating and an average price target of $8.50, despite recent sell-rating actions from some research providers.
• Aquestive reported quarterly revenue of $13.82 million, ahead of estimates, but its adjusted loss of $0.18 per share missed expectations of a $0.10 loss. Shares recently opened at $4.66, with a 52-week range of $2.93 to $7.55.

Bratton Capital Management L.P. bought a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 9,810,958 shares of the company's stock, valued at approximately $40,813,585,000. Aquestive Therapeutics comprises 100.0% of Bratton Capital Management L.P.'s portfolio, making the stock its largest position. Bratton Capital Management L.P. owned approximately 7.82% of Aquestive Therapeutics as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. NewEdge Advisors LLC acquired a new stake in shares of Aquestive Therapeutics in the third quarter worth $28,000. BNP Paribas Financial Markets increased its holdings in shares of Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after purchasing an additional 4,134 shares in the last quarter. Modern Wealth Management LLC acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $33,000. Elevation Point Wealth Partners LLC purchased a new stake in Aquestive Therapeutics during the first quarter worth $42,000. Finally, ADAR1 Capital Management LLC grew its position in Aquestive Therapeutics by 103.9% during the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company's stock valued at $42,000 after buying an additional 264,000 shares during the period. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on AQST shares. Oppenheimer initiated coverage on Aquestive Therapeutics in a research report on Friday, April 24th. They issued an "outperform" rating and a $8.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aquestive Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen lowered shares of Aquestive Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $8.50.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $4.66 on Friday. The business has a 50 day moving average price of $4.18 and a 200 day moving average price of $4.12. The company has a market capitalization of $584.88 million, a P/E ratio of -7.17 and a beta of 1.49. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. As a group, research analysts expect that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current fiscal year.

Insiders Place Their Bets

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the transaction, the director owned 25,000 shares of the company's stock, valued at $125,500. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by corporate insiders.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.

Want to see what other hedge funds are holding AQST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source